Mid-Atlantic Biotherapeutics
Pre-clinicalMid-Atlantic BioTherapeutics is thrilled to announce the acquisition of XPose Therapeutics, a transformative milestone that expands our oncology pipeline and accelerates our mission to deliver breakthrough therapies to patients in need. XPose brings cutting-edge expertise in targeting “undruggable” DNA Damage Response (DDR) proteins for cancer treatment, perfectly complementing MABT’s immunotherapy platform and commitment to precision oncology.
About
Mid-Atlantic BioTherapeutics is thrilled to announce the acquisition of XPose Therapeutics, a transformative milestone that expands our oncology pipeline and accelerates our mission to deliver breakthrough therapies to patients in need. XPose brings cutting-edge expertise in targeting “undruggable” DNA Damage Response (DDR) proteins for cancer treatment, perfectly complementing MABT’s immunotherapy platform and commitment to precision oncology.
Funding History
2Total raised: $18M
Company Info
Contact
Sectors
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile